Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome

Respiration

Volumn 87, Issue 4, 2014, Pages 329-342

  Barratt, S ^a,c   Medford, A R ^b,c   Millar, A B ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; BEVACIZUMAB; NEUROPILIN 1; NEUROPILIN 2; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD VESSEL PERMEABILITY; CAPILLARY WALL; HUMAN; LUNG EDEMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; CELL PROLIFERATION; FIBROBLAST; GENETIC POLYMORPHISM; LUNG FIBROSIS; LUNG FUNCTION; LUNG HEMORRHAGE; MOLECULAR BIOLOGY; PROTEIN FUNCTION; ANIMAL; LUNG; METABOLISM; PHYSIOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT;

ACUTE LUNG INJURY; ANIMALS; HUMANS; LUNG; NEUROPILIN-1; NEUROPILIN-2; RESPIRATORY DISTRESS SYNDROME, ADULT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84898602379     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000356034     Document Type: Review

References (141)

1. Katzenstein AL, Bloor CM, Leibow AA: Diffuse alveolar damage -The role of oxygen, shock, and related factors. A review. Am J Pathol 1976; 85: 209-228.
2. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE: Acute respiratory distress in adults. Lancet 1967;ii:319-323.
3. Matthay MA, Zimmerman GA: Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005; 33: 319-327.
4. Spragg RG, Bernard GR, Checkley W, Curtis JR, Gajic O, Guyatt G, Hall J, Israel E, Jain M, Needham DM, Randolph AG, Rubenfeld GD, Schoenfeld D, Thompson BT, Ware LB, Young D, Harabin AL: Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med 2010; 181: 1121-1127.
5. Li G, Malinchoc M, Cartin-Ceba R, Venkata CV, Kor DJ, Peters SG, Hubmayr RD, Gajic O: Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am J Respir Crit Care Med 2011; 183: 59-66.
6. Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, Lowell CA, Norris PJ, Murphy EL, Weiskopf RB, Wilson G, Koenigsberg M, Lee D, Schuller R, Wu P, Grimes B, Gandhi MJ, Winters JL, Mair D, Hirschler N, Sanchez Rosen R, Matthay MA: Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119: 1757-1767.
7. Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JC, Mercat A, Brochard L, Brun-Buisson C, Chastre J: Longterm outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest 2012; 142: 583-592.
8. Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C: Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease -12-month follow-up: angiogenic gene therapy. J Intern Med 2001; 250: 373-381.
9. Armstrong L, Thickett DR, Mansell JP, Ionescu M, Hoyle E, Billinghurst RC, Poole AR, Millar AB: Changes in collagen turnover in early acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160: 1910-1915.
10. Plouet J, Schilling J, Gospodarowicz D: Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3801-3806.
11. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
12. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, OShea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442.
13. Monacci WT, Merrill MJ, Oldfield EH: Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 1993; 264:C995-C1002.
14. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220.
15. Medford AR, Millar AB: Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm? Thorax 2006; 61: 621-626.
16. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
17. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
18. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858.
19. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-11954.
20. Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-1326.
21. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-26037.
22. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62: 4123-4131.
23. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271: 5638-5646.
24. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO: VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-7835.
25. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U: Vascular endothelial growth factor b (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-11714.
26. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 1751.
27. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996; 93: 2576-2581.
28. Yamazaki Y, Morita T: Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006; 10: 515-527.
29. Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, Eriksson U, Alitalo K: Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 1999; 274: 21217-21222.
30. Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, Mould A, Cahill MM, Tonks ID, Grimmond SM, Townson S, Wells C, Little M, Cummings MC, Hayward NK, Kay GF: Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000; 86:E29-E35.
31. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, Scotney P, Lee C, Arjunan P, Dong L, Kumar A, Rissanen TT, Wang B, Nagai N, Fons P, Fariss R, Zhang Y, Wawrousek E, Tansey G, Raber J, Fong GH, Ding H, Greenberg DA, Becker KG, Herbert JM, Nash A, Yla-Herttuala S, Cao Y, Watts RJ, Li X: VEGFB is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009; 106: 6152-6157.
32. Wanstall JC, Gambino A, Jeffery TK, Cahill MM, Bellomo D, Hayward NK, Kay GF: Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res 2002; 55: 361-368.
33. Louzier V, Raffestin B, Leroux A, Branellec D, Caillaud JM, Levame M, Eddahibi S, Adnot S: Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2003; 284:L926-L937.
34. Mura M, dos Santos CC, Stewart D, Liu M: Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol 2004; 97: 1605-1617.
35. Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K: Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 2007; 204: 1431-1440.
36. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-553.
37. Saaristo A, Veikkola T, Enholm B, Hytonen M, Arola J, Pajusola K, Turunen P, Jeltsch M, Karkkainen MJ, Kerjaschki D, Bueler H, Yla-Herttuala S, Alitalo K: Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J 2002; 16: 1041-1049.
38. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
39. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M: A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998; 273: 31273-31282.
40. Persico MG, Vincenti V, DiPalma T: Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999; 237: 31-40.
41. Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-25654.
42. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Shibuya M, Collen D, Conway EM, Carmeliet P: Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
43. Tsao PN, Su YN, Li H, Huang PH, Chien CT, Lai YL, Lee CN, Chen CA, Cheng WF, Wei SC, Yu CJ, Hsieh FJ, Hsu SM: Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med 2004; 169: 505-511.
44. Sands M, Howell K, Costello CM, McLoughlin P: Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir Res 2011; 12: 17.
45. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 3566-3570.
46. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7: 575-583.
47. Matsumoto T, Claesson-Welsh L: Vegf receptor signal transduction. Sci STKE 2001; 2001:re21.
48. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-846.
49. Norden AD, Drappatz J, Wen PY: Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5: 610-620.
50. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
51. Fehrenbach H, Haase M, Kasper M, Koslowski R, Schuh D, Muller M: Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flk1 and Flt1 in bleomycin-induced rat lung fibrosis. Virchows Arch 1999; 435: 20-31.
52. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
53. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M: Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 1998; 273: 31283-31288.
54. Takahashi T, Shirasawa T, Miyake K, Yahagi Y, Maruyama N, Kasahara N, Kawamura T, Matsumura O, Mitarai T, Sakai O: Protein tyrosine kinases expressed in glomeruli and cultured glomerular cells: Flt-1 and VEGF expression in renal mesangial cells. Biochem Biophys Res Commun 1995; 209: 218-226.
55. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M: Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocytemacrophages in humans. Blood 2001; 97: 785-791.
56. Maniscalco WM, Watkins RH, DAngio CT, Ryan RM: Hyperoxic injury decreases alveolar epithelial cell expression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung. Am J Respir Cell Mol Biol 1997; 16: 557-567.
57. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-26995.
58. Kendall RL, Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709.
59. Fuh G, Li B, Crowley C, Cunningham B, Wells JA: Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 1998; 273: 11197-11204.
60. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L: Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437: 169-183.
61. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE: VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010; 17: 499-512.
62. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y: Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000; 19: 2138-2146.
63. Kitsukawa T, Shimizu M, Sanbo M, Hirata T, Taniguchi M, Bekku Y, Yagi T, Fujisawa H: Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 1997; 19: 995-1005.
64. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD: Neuropilin is a semaphorin III receptor. Cell 1997; 90: 753-762.
65. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M: Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 1997; 19: 547-559.
66. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoformspecific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745.
67. Parker MW, Xu P, Li X, Vander Kooi CW: Structural basis for the selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 2012; 287: 11082-11089.
68. Medford AR, Ibrahim NB, Millar AB: Vascular endothelial growth factor receptor and coreceptor expression in human acute respiratory distress syndrome. J Crit Care 2009; 24: 236-242.
69. Soker S, Fidder H, Neufeld G, Klagsbrun M: Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996; 271: 5761-5767.
70. Brusselmans K, Bono F, Collen D, Herbert JM, Carmeliet P, Dewerchin M: A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem 2005; 280: 3493-3499.
71. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, Van Dorpe J, Hellings P, Gorselink M, Heymans S, Theilmeier G, Dewerchin M, Laudenbach V, Vermylen P, Raat H, Acker T, Vleminckx V, Van Den Bosch L, Cashman N, Fujisawa H, Drost MR, Sciot R, Bruyninckx F, Hicklin DJ, Ince C, Gressens P, Lupu F, Plate KH, Robberecht W, Herbert JM, Collen D, Carmeliet P: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001; 28: 131-138.
72. Pidgeon GP, Barr MP, Cathcart MC, Gray S, OByrne KJ: Neuropilin-1 expression in adenocarcinoma and squamous cell carcinoma of the lung is differentially regulated by hypoxia. J Clin Oncol 24(suppl 18s):679s, abstr 17152.
73. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
74. Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K: Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010; 1804: 567-580.
75. Le A, Zielinski R, He C, Crow MT, Biswal S, Tuder RM, Becker PM: Pulmonary epithelial neuropilin-1 deletion enhances development of cigarette smoke-induced emphysema. Am J Respir Crit Care Med 2009; 180: 396-406.
76. Kaner RJ, Crystal RG: Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med 2001; 7: 240-246.
77. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
78. Yao JS, Shen F, Young WL, Yang GY: Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int 2007; 50: 524-530.
79. Wu WK, Llewellyn OP, Bates DO, Nicholson LB, Dick AD: IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology 2010; 215: 796-803.
80. Mura M, Han B, Andrade CF, Seth R, Hwang D, Waddell TK, Keshavjee S, Liu M: The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. Crit Care 2006; 10:R130.
81. Roberts JR, Perkins GD, Fujisawa T, Pettigrew KA, Gao F, Ahmed A, Thickett DR: Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit Care Med 2007; 35: 2164-2170.
82. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3 ? -kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
83. Shifren JL, Doldi N, Ferrara N, Mesiano S, Jaffe RB: In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action. J Clin Endocrinol Metab 1994; 79: 316-322.
84. Kuhn H, Kruger S, Hammerschmidt S, Wirtz H: High concentrations of vascular endothelial growth factor reduce stretch-induced apoptosis of alveolar type II cells. Respirology 2010; 15: 343-348.
85. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
86. Brown KR, England KM, Goss KL, Snyder JM, Acarregui MJ: VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol 2001; 281:L1001-L1010.
87. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, Carmeliet P: Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002; 8: 702-710.
88. Gerber HP, Dixit V, Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-13316.
89. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA: Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003; 301: 94-96.
90. Tang K, Rossiter HB, Wagner PD, Breen EC: Lung-Targeted VEGF inactivation leads to an emphysema phenotype in mice. J Appl Physiol 2004; 97: 1559-1566, discussion 1549.
91. Mura M, Binnie M, Han B, Li C, Andrade CF, Shiozaki A, Zhang Y, Ferrara N, Hwang D, Waddell TK, Keshavjee S, Liu M: Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. Am J Pathol 2010; 176: 1725-1734.
92. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000; 106: 1311-1319.
93. Tuder RM, Kasahara Y, Voelkel NF: Inhibition of vascular endothelial growth factor receptors causes emphysema in rats. Chest 2000; 117: 281S.
94. Guan XJ, Song L, Han FF, Cui ZL, Chen X, Guo XJ, Xu WG: Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary function partly via VEGF-VEGF receptors. J Cell Biochem 2013; 114: 323-335.
95. Le Cras TD, Spitzmiller RE, Albertine KH, Greenberg JM, Whitsett JA, Akeson AL: VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am J Physiol Lung Cell Mol Physiol 2004; 287:L134-L142.
96. Bhandari V, Choo-Wing R, Chapoval SP, Lee CG, Tang C, Kim YK, Ma B, Baluk P, Lin MI, McDonald DM, Homer RJ, Sessa WC, Elias JA: Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc Natl Acad Sci USA 2006; 103: 11021-11026.
97. Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Yla-Herttuala S, Nykanen AI, Lemstrom KB: Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. Am J Pathol 2012; 181: 1607-1620.
98. Medford AR, Godinho SI, Keen LJ, Bidwell JL, Millar AB: Relationship between vascular endothelial growth factor + 936 genotype and plasma/epithelial lining fluid vascular endothelial growth factor protein levels in patients with and at risk for ARDS. Chest 2009; 136: 457-464.
99. Medford AR, Keen LJ, Bidwell JL, Millar AB: Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome. Thorax 2005; 60: 244-248.
100. Yang S, Cao S, Li J, Chang J: Association between vascular endothelial growth factor + 936 genotype and acute respiratory distress syndrome in a Chinese population. Genet Test Mol Biomarkers 2011; 15: 737-740.
101. Kim JY, Hildebrandt MA, Pu X, Ye Y, Correa AM, Vaporciyan AA, Wu X, Roth JA: Variations in the vascular endothelial growth factor pathway predict pulmonary complications. Ann Thorac Surg 2012; 94: 1079-1085.
102. Simpson A, Custovic A, Tepper R, Graves P, Stern DA, Jones M, Hankinson J, Curtin JA, Wu J, Blekic M, Bukvic BK, Aberle N, Marinho S, Belgrave D, Morgan WJ, Martinez FD: Genetic variation in vascular endothelial growth factor-A and lung function. Am J Respir Crit Care Med 2012; 185: 1197-1204.
103. Thickett DR, Armstrong L, Millar AB: A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med 2002; 166: 1332-1337.
104. Maitre B, Boussat S, Jean D, Gouge M, Brochard L, Housset B, Adnot S, Delclaux C: Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J 2001; 18: 100-106.
105. Azamfirei L, Gurzu S, Solomon R, Copotoiu R, Copotoiu S, Jung I, Tilinca M, Branzaniuc K, Corneci D, Szederjesi J, Kovacs J: Vascular endothelial growth factor: a possible mediator of endothelial activation in acute respiratory distress syndrome. Minerva Anestesiol 2010; 76: 609-616.
106. Bardales RH, Xie SS, Schaefer RF, Hsu SM: Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am J Pathol 1996; 149: 845-852.
107. Martin TR, Nakamura M, Matute-Bello G: The role of apoptosis in acute lung injury. Crit Care Med 2003; 31:S184-S188.
108. Tuder RM, Flook BE, Voelkel NF: Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798-1807.
109. Koehne P, Willam C, Strauss E, Schindler R, Eckardt KU, Buhrer C: Lack of hypoxic stimulation of VEGF secretion from neutrophils and platelets. Am J Physiol Heart Circ Physiol 2000; 279:H817-H824.
110. Medford AR, Douglas SK, Godinho SI, Uppington KM, Armstrong L, Gillespie KM, van Zyl B, Tetley TD, Ibrahim NB, Millar AB: Vascular endothelial growth factor (VEGF) isoform expression and activity in human and murine lung injury. Respir Res 2009; 10: 27.
111. Jakobsson L, Kreuger J, Holmborn K, Lundin L, Eriksson I, Kjellen L, Claesson-Welsh L: Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell 2006; 10: 625-634.
112. Perkins GD, Roberts J, McAuley DF, Armstrong L, Millar A, Gao F, Thickett DR: Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury. Thorax 2005; 60: 153-158.
113. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J: Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997; 90: 4153-4161.
114. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629-17634.
115. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG: Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 2000; 22: 657-664.
116. Watanabe M, Boyer JL, Crystal RG: Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced highpermeability pulmonary edema. Hum Gene Ther 2009; 20: 598-610.
117. Godzich M, Hodnett M, Frank JA, Su G, Pespeni M, Angel A, Howard MB, Matthay MA, Pittet JF: Activation of the stress protein response prevents the development of pulmonary edema by inhibiting VEGF cell signaling in a model of lung ischemia-reperfusion injury in rats. FASEB J 2006; 20: 1519-1521.
118. Carpenter T, Schomberg S, Steudel W, Ozimek J, Colvin K, Stenmark K, Ivy DD: Endothelin B receptor deficiency predisposes to pulmonary edema formation via increased lung vascular endothelial cell growth factor expression. Circ Res 2003; 93: 456-463.
119. Karmpaliotis D, Kosmidou I, Ingenito EP, Hong K, Malhotra A, Sunday ME, Haley KJ: Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2002; 283:L585-L595.
120. Lange M, Hamahata A, Traber DL, Connelly R, Nakano Y, Traber LD, Schmalstieg FC, Herndon DN, Enkhbaatar P: Pulmonary microvascular hyperpermeability and expression of vascular endothelial growth factor in smoke inhalation-and pneumoniainduced acute lung injury. Burns 2012; 38: 1072-1078.
121. Hu XH, Duan YY, Li Y, Xue ZQ: Early responses of VEGF during acute lung injury induced by seawater immersion after open chest trauma. Respiration 2010; 79: 490-496.
122. Jesmin S, Zaedi S, Islam AM, Sultana SN, Iwashima Y, Wada T, Yamaguchi N, Hiroe M, Gando S: Time-dependent alterations of VEGF and its signaling molecules in acute lung injury in a rat model of sepsis. Inflammation 2012; 35: 484-500.
123. Gillette MA, Hess DR: Ventilator-induced lung injury and the evolution of lung-protective strategies in acute respiratory distress syndrome. Respir Care 2001; 46: 130-148.
124. Li LF, Huang CC, Liu YY, Lin HC, Kao KC, Yang CT, Liao SK: Hydroxyethyl starch reduces high stretch ventilation-augmented lung injury via vascular endothelial growth factor. Transl Res 2011; 157: 293-305.
125. Bellingan GJ: The pulmonary physician in critical care 6: the pathogenesis of ALI/ARDS. Thorax 2002; 57: 540-546.
126. Varet J, Douglas SK, Gilmartin L, Medford AR, Bates DO, Harper SJ, Millar AB: VEGF in the lung: a role for novel isoforms. Am J Physiol Lung Cell Mol Physiol 2010; 298:L768-L774.
127. Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X, Chen L: VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 2009; 9: 70-79.
128. Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K, Nakashima N, Maeyama T, Yoshimi M, Nakanishi Y: Antivascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005; 175: 1224-1231.
129. Stockmann C, Kerdiles Y, Nomaksteinsky M, Weidemann A, Takeda N, Doedens A, Torres-Collado AX, Iruela-Arispe L, Nizet V, Johnson RS: Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci USA 2010; 107: 4329-4334.
130. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML: Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703.
131. Abadie Y, Bregeon F, Papazian L, Lange F, Chailley-Heu B, Thomas P, Duvaldestin P, Adnot S, Maitre B, Delclaux C: Decreased VEGF concentration in lung tissue and vascular injury during ARDS. Eur Respir J 2005; 25: 139-146.
132. Maniscalco WM, Watkins RH, Finkelstein JN, Campbell MH: Vascular endothelial growth factor mRNA increases in alveolar epithelial cells during recovery from oxygen injury. Am J Respir Cell Mol Biol 1995; 13: 377-386.
133. Corne J, Chupp G, Lee CG, Homer RJ, Zhu Z, Chen Q, Ma B, Du Y, Roux F, McArdle J, Waxman AB, Elias JA: IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J Clin Invest 2000; 106: 783-791.
134. He CH, Waxman AB, Lee CG, Link H, Rabach ME, Ma B, Chen Q, Zhu Z, Zhong M, Nakayama K, Nakayama KI, Homer R, Elias JA: Bcl-2-related protein A1 is an endogenous and cytokine-stimulated mediator of cytoprotection in hyperoxic acute lung injury. J Clin Invest 2005; 115: 1039-1048.
135. Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, Voelkel NF, Flores SC: Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88-97.
136. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
137. Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
138. Ferrara N, Hillan KJ, Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-335.
139. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME: Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27: 331-371.
140. Chen HX, Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-477.
141. Roth DA, McKirnan MD, Canestrelli I, Gao MH, Dalton N, Lai NC, Roth DM, Hammond HK: Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus. Hum Gene Ther 2006; 17: 230-238